Synergy CHC Corp (SNYR) is a consumer health company that develops and sells branded nutritional supplements and ready-to-drink beverages. Revenue comes from transactional product sales through retail channels, with third-party manufacturers producing all physical goods under an asset-light model. The company built its brand portfolio through acquisitions, purchasing FOCUSfactor in January 2015 for $6.0 million and Flat Tummy in November 2015 for approximately $7.0 million (AUD 10.0 million). FOCUSfactor is the flagship brand, a brain health supplement with over 25 years of history and a 52-ingredient clinically tested formula, grown from 3 SKUs at acquisition to over 34 SKUs as of the FY2025 10-K filed April 1, 2026. Flat Tummy expanded from 1 SKU to 13 SKUs over the same period. The company has expanded FOCUSfactor into energy ready-to-drink products, targeting a U.S. energy RTD market reported at $19.2 billion in 2023. Capital structure has been highly levered since the 2015 acquisitions, with multiple senior subordinated debentures outstanding.

Revenue model

Transactional product sales of branded nutritional supplements and ready-to-drink beverages through retail channels. Products are manufactured by third-party suppliers under an asset-light model, with the company owning brand IP and managing distribution relationships.

Products and services

FOCUSfactor brain health nutritional supplements (34+ SKUs as of filing date), FOCUSfactor energy ready-to-drink beverages, and Flat Tummy brand products (13 SKUs as of filing date).

Customers and end markets

Retail consumers purchasing through large retail chains where FOCUSfactor has established presence. Target demographics include supplement consumers over age 50 and a younger demographic aged 18 to 49 for RTD products. Customer concentration risk is disclosed as material, with reliance on one or more largest customers noted as a key risk.

Value-chain role

Brand owner and distributor. Synergy CHC holds brand IP and retail relationships while outsourcing all manufacturing to third-party suppliers. The company does not operate its own production facilities.

Geographic exposure

Primary operations in the United States. International expansion into additional markets is disclosed as a planned strategic initiative as of the FY2025 10-K filed April 1, 2026, but not yet executed at material scale.

Competitors

Celsius, Bang, Reign, C4

Source: SEC 10-K, filed 2026-04-01

Industry: Medicinal Chemicals & Botanical Products